Therapeutics News and Research

RSS
Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

First-quarter fiscal 2010 results announced by Senesco Technologies

First-quarter fiscal 2010 results announced by Senesco Technologies

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Recent developments at Burnham Institute for Medical Research

Recent developments at Burnham Institute for Medical Research

LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics discovers orally available PARP inhibitor

VCU and RAA have improved resuscitation and survival rates for cardiac arrest patients

VCU and RAA have improved resuscitation and survival rates for cardiac arrest patients

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

HDAC inhibitors: New therapy for treating breast cancer

HDAC inhibitors: New therapy for treating breast cancer

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics announces the completion of $30 million Series B financing

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces Phase 3 trial results of Genasense

Genta announces Phase 3 trial results of Genasense

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

EntreMed announces financial results for the third quarter of 2009

EntreMed announces financial results for the third quarter of 2009

Lack of hemophilia treatment in the developing world costing lives

Lack of hemophilia treatment in the developing world costing lives

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.